{"id":"NCT02760433","sponsor":"R-Pharm International, LLC","briefTitle":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","officialTitle":"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-25","primaryCompletion":"2019-09-12","completion":"2019-10-01","firstPosted":"2016-05-03","resultsPosted":"2021-07-21","lastUpdate":"2023-09-21"},"enrollment":368,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Olokizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm 1: Olokizumab q4w","type":"EXPERIMENTAL"},{"label":"Arm 2: Olokizumab q2w","type":"EXPERIMENTAL"},{"label":"Arm 3: Placebo q2w","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor\n\nThe primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.","primaryOutcome":{"measure":"Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response","timeFrame":"at Week 12","effectByArm":[{"arm":"Arm 1: Olokizumab 64 mg q4w","deltaMin":96,"sd":null},{"arm":"Arm 2: Olokizumab 64 mg q2w","deltaMin":84,"sd":null},{"arm":"Arm 3: Placebo q2w","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.004"},{"comp":"OG001 vs OG002","p":"0.0029"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":30},"locations":{"siteCount":116,"countries":["United States","Argentina","Brazil","Colombia","Czechia","Germany","Hungary","Mexico","Poland","Russia","South Korea"]},"refs":{"pmids":["36109142"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":160},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Nasopharyngitis","Upper respiratory tract infection","Latent tuberculosis"]}}